Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Okereke, Ikenna; Gangadharan, Sidhu P.; Kent, Michael S.; Nicotera, Saila P.; Shen, Changyu; DeCamp, Malcolm M.

doi:10.1016/j.athoracsur.2009.05.083

Cited by 45 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It seems to be contradictory that tumors with a high pretreatment SUV would respond better to initial chemotherapy. Recently, the SUV max of the primary tumor was described to be higher than that of the metastatic lesions [15], and this was consistent with our results. Moreover, Sekine et al [16] described that OS and PFS after chemotherapy were superior in NSCLC patients with postoperative recurrence than in those with stage IV disease.…”

Section: Discussionsupporting

confidence: 93%

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…A correlation between pre-operative FDG uptake, pathological stage, probability of nodal metastasis and outcomes has also been reported for the spectrum of adenocarcinoma associated with focal GGOs and for stage I NSCLC in general [43,61,[68][69][70][71].…”

Section: Fdg Uptakementioning

confidence: 99%

Slow-growing lung cancer as an emerging entity: from screening to clinical management

et al. 2013

View full text Add to dashboard Cite

The current paradigm is that untreated lung cancer is invariably and rapidly fatal, therefore the medical community normally dismisses the idea that a patient could live with such a disease for years without any therapy.Yet evidence from lung cancer screening research and from recent clinical series suggests that, although rarely recognised in routine practice, slow-growing lung cancers do exist and are more common than previously thought.Here, current evidence is reviewed and clinical cases are illustrated to show that slow-growing lung cancer is a real clinical entity, and the reasons why management protocols developed in the screening setting may also be useful in clinical practice are discussed. Features suggesting that a lung cancer may be slow-growing are described and appraised, areas of uncertainty are examined, modern management options for earlystage disease are evaluated and the influence that all this knowledge might have on our clinical decisionmaking is weighed. Further research directed at developing appropriate guidelines for these peculiar but increasingly common patients is warranted. @ERSpublications The increasingly common incidence of slow-growing lung cancer and its influence on clinical decision-making is discussed

show abstract

“…The SUV, which measures the uptake and trapping of radiolabeled glucose by tissues, and the maximal SUV of the primary tumor may therefore reflect the biological malignant potential of non-small cell lung carcinoma (NSCLC) [12]. Okereke et al reported that the SUV exhibits a strong correlation with survival and that a higher SUVmax predicts a poor survival outcome in patients with NSCLC [13]. Elnayal et al showed that FDG uptake was much higher in ACC (SUVmax : median, 8.6; range, 3.7 -17.6) than in other salivary gland-type tumors of the lung, although increased FDG uptake didnʼt translate into worse overall survival or progression-free survival time [14].…”

Section: Discussionmentioning

confidence: 99%

Primary Adenoid Cystic Carcinoma of the Peripheral Lungs

Shinohara

Hanagiri

Takenaka

et al. 2015

J UOEH

View full text Add to dashboard Cite

: We herein report a very rare case of adenoid cystic carcinoma of the peripheral lungs. A 77-year-old female visited a family physician for aortitis syndrome, diabetes mellitus and hyperlipidemia. A follow-up chest computed tomography scan for aortitis syndrome revealed a nodule in the middle lobe of the right lung. Although a transbronchial lung biopsy was attempted, a definitive diagnosis could not be made. Because the possibility of lung malignancy could not be ruled out, thoracoscopic wedge resection of the middle lobe was performed. The intraoperative pathological diagnosis revealed carcinoma of the lungs and we performed middle lobectomy under complete video-assisted thoracoscopic surgery. A histopathological examination demonstrated an adenoid cystic carcinoma with a characteristic cribriform structure.

show abstract

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Cited by 45 publications

References 12 publications

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer

Slow-growing lung cancer as an emerging entity: from screening to clinical management

Primary Adenoid Cystic Carcinoma of the Peripheral Lungs

Contact Info

Product

Resources

About